Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
11 participants
INTERVENTIONAL
2020-01-03
2020-05-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hence, the objective of the study is to investigate the effect of Oxyjun on aerobic fitness in physically active overweight and obese individuals. All subjects in the study will be tested for maximum aerobic capacity , body composition, and serum biomarker for fitness.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy of OxyjunTM on Cardiac Pumping Capacity as Well as Work Productivity in Individuals With Metabolic Risk.
NCT06496880
Evaluate Efficacy of Oxyjun on Cardiovascular Health in Healthy Individuals.
NCT04715126
Study to Assess the Effect of OXYJUN on Ejection Fraction and Markers of Cardiovascular Injury
NCT02207101
To Study the Effect of Investigational Product on Fatigue and Cardiorespiratory Fitness in Healthy Adults.
NCT05621395
The Long-term Effects of Oceanix™ on Resistance Training Adaptations
NCT04136821
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxyjun
Oxyjun- 400 mg OD after breakfast
Oxyjun
Oxyjun is the proprietary single ingredient product containing high concentrated well standardized aqueous extract of Terminalia arjuna.
Methyl Crystalline Cellulose
Methyl Crystalline Cellulose- 400 mg OD after breakfast
Pacebo
Methyl Crystalline Cellulose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxyjun
Oxyjun is the proprietary single ingredient product containing high concentrated well standardized aqueous extract of Terminalia arjuna.
Pacebo
Methyl Crystalline Cellulose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Waist Circumference ≥ 80 cms.
* Non-smoker.
* BP ≤ 140/90 mm Hg
* FBS ≤ 125 mg/dl
* Hb ≥ 11 g/ dl
* Can abstain from strenuous exercise and alcohol for at least 48 hours.
* Can abstain from caffeine for at least 24 hours.
Exclusion Criteria
* Inter-arm blood pressure is ≥10 mm Hg.
* Known cases of type II Diabetes Mellitus.
* Known cases of hypertension with or without anti-hypertensive medication.
* Visual or balance problems, or who cannot walk on a treadmill without using the handrails.
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vedic Lifesciences Pvt. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vedic Lifesciences Pvt. Ltd
Mumbai, Opp Infinity Mall, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EB/181201/OXYJUN/EVRG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.